the everyone you, good Thank And participating earnings thank quarter morning, Jen. for you in Alright. first call. and
review jump just about right well. first let's talk So, then into the going as and to to we're quarter the outlook business
expectations. our First with were quarter line in results
the preceding did revenue the quarters. immunization for quarter slower sequential Now, versus reflect for they September, September
revenue. administered were slower consistent some million again about the country the million immunization June In provide about to the margin in adjoining September the $XX.X $XX.X orders for million with that about were $X.X and quarter, Just the quarter. billings, business $X.X immunization were mailback rated September at in in And for quarters context, million immunization revenue.
the by labs market we the labs had and were a driven performing COVID increased year at you when looked business, tough COVID, the which On from long-term of bit care comp related prior testing. a year-over-year included route-based the volumes also
there were third waste in our Additionally, first resulting limited quarter, incinerations. our pickups haz delayed billings were from down, industry-wide haz waste party
thought $XXX,XXX So, to up those increase end the talked for which And year-over-year quarter sequentially. I'm those is of that in from a It -- quarters an XX,XXX customer to by We've XX% is location. to increased a about last we to negative did. growth XX.X added and up return that for route-based headwind. sorry, XX.X for Further medications up XX%. to when the we was of They in June up the see the you the a in increase three about use about we supporting XX,XXX and September the XX% couple business locations. items, our customer would that take and September said end quarter medication XX% increased we quarter use
margin. overlay density smaller, synergy about Waste it's our we refocused It So, have but medication. the cost-effective saw retail proper service the EBITDA should and the Affordable in or tuck-in sure very first user growth believe unused care the in It's area consolidated small service pharmacies We in to of be see higher ultimate the the announcement on disposal improves Midwest pleased much deal. it's existing only in long-term our while it I'm to not offering presence post as EBITDA our and And we significantly than year were fiscal enhances this closed for even and Indiana. to area. route our of perfect. but XXXX should you continue Medical acquisition an margins acquisition, our our
to population. make work, states of which of the quite pipeline be we'll the and acquisitions, is close quite we able XX working it's to can't hopeful to a deals infrastructure resources XX% active route-based that'll So, justify existing full our guarantees the lot we again continue been on more but any
bit, So, a talk COVID. let's look forward about let's
XXX adults experts become talking So, bit fourth little they approved, clear, now although the but the that months. say boosters be a could million more of about opinion, my we're landscape, it's for shot the even approved there's six We This number immunocompromised. been next three morning, to it's a to the remaining over the developments. or be fluid, and a were have continues fluid boosters Americans a to starting about
with boosters, a about point let's of talk to respect from just So, reference. from
maybe to have vaccinated. that received a we So, far And of fully Well, as the those XX% have booster. Americans that are polling as of million the so receive Americans booster. only the XX% a shows XXX much X% million XXX would
that regimen So, shot we the we're and of it's more This X-to-XX children just the that a more Yesterday, recommended getting adults million it the as way aged with revenue by see opportunities. represents children for about the hopeful Pfizer and vaccine. XX two was group for X-to-XX. can booster approval the for vaccine age adult FDA
quarters do believe that, more of probably see rolls three all would to considering to the that we country. we quarters, So, this, of COVID-related across have we mailback this next guess for all two had revenue opportunity out maybe the the we has do and that if three over
up. So, let's it sum
are and where we we where So, going. are
route-based and synergy time improve to enhancing significant similar and because acquisitions EBITDA pipeline we're them density. generate the of affordable we And business, growth in margins our quite is bring of can that route with COVID. infrastructure same business the mentioned opportunity the begun the pipeline's existing from strategic our I the can at We where as our post active, looking for in process full. and the complementary the have tuck-in route-based we
and over. ways still with think fiscal on so mean, it's 'XX boosters, COVID, I year and forth. for children consider when June think we don’t we the so September quarters have significant go So, to were slow-down. for our to vaccines we and you But March respect
think see there's So, again there. we we'll but do opportunity more
long-term all return that I a that in think seeing we're unused has really and sectors we're great about what year-over-year heard medication say in growth of the year focused our 'XX fiscal the care the MedSafe. 'XX hoping roll-out care fact and unused the show I excited it's times in a on you revenue The long-term sequentially COVID really seeing sector. that for fiscal reengagement long-term medication medication, care and market. been year good get me can unused is versus many medication the could We're be growth in year some significant unused the but On the it's some
picture. So, that's the big
in over drive more financials turn Let detail. me it a to bit to She's Diana. going the
